The shortage of organs for transplantation has increased utilization of organs from donors potentially or known to be from donors carrying various infections. Our data has shown that careful use of US PHS increased risk donation is safe as long as recipients are carefully monitored after transplantation. Use of HCV-positive organs requires development of both a safety infrastructure and a research program in advance to avoid undetected transmission, to recognize reactivation of hepatitis B virus and of HCV following HCV-antiviral therapies (DAA failures), to detect premature liver graft failures or excess opportunistic infections (if any), and to study any shifts in risk for recurrence of hepatocellular carcinoma in liver recipients. Successes to date in the use of HCV-infected grafts should not prevent development of knowledge regarding the limitations of this technology.
The participant will understand the gaps in the knowledge regarding the efficacy of DAA therapy:
